Shares of biotech company Trimeris Inc. soared 26 percent in late trading after the biopharmaceutical company swung to a profit sales more than doubled to top Wall Street expectations.

The Morrisville, N.C.-based biotech and pharma company said the increase came mainly from royalties from the HIV drug Fuzeon. Trimeris' partner on the drug, Roche Holding, posted a 29 percent rise in global sales to $63 million for the drug during the quarter.

Shares of Trimeris surged in after-hours electronic trading, rising $2.07, or 26 percent, to $10. Shares closed up 2.7 percent, at $7.93 on the Nasdaq.